Base de dados : MEDLINE
Pesquisa : D06.472.334 [Categoria DeCS]
Referências encontradas : 500 [refinar]
Mostrando: 1 .. 10   no formato [Detalhado]

página 1 de 50 ir para página                         

  1 / 500 MEDLINE  
              next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29261765
[Au] Autor:Levy T; Rosen O; Simons O; Savaya Alkalay A; Sagi A
[Ad] Endereço:Department of Life Sciences, Ben-Gurion University of the Negev, Beer-Sheva, Israel.
[Ti] Título:The gene encoding the insulin-like androgenic gland hormone in an all-female parthenogenetic crayfish.
[So] Source:PLoS One;12(12):e0189982, 2017.
[Is] ISSN:1932-6203
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Male sexual differentiation in crustaceans is controlled by the androgenic gland (AG), a unique male endocrine organ that, in decapods, is located at the base of the 5th pereiopod. In these animals, the insulin-like androgenic gland hormone (IAG) is the major factor secreted from the AG to induce masculinization and maintain male characteristics. It has, however, recently been proposed that this hormone also plays a role in growth and ovarian development in females. In this study, we tested such a possibility by searching for the IAG gene in the marbled crayfish, a parthenogenetic animal that reproduces asexually to form an all-female genetic clone. Based on the phylogenetic relationship between the marbled crayfish and Procambarus fallax, a gonochoristic species of the same North American Cambaridae family, we searched for the IAG gene in the marbled crayfish and then fully sequenced it. The open reading frame of the gene was found to be completely identical in the two species, and their introns shared over 94% identity. It was also found that, in addition to its expression at the base of the 5th pereiopod and in the testes of male P. fallax crayfish, IAG was expressed in the muscle tissue of P. fallax males and females and even of the parthenogenetic marbled crayfish. These findings provide new insight into possible functions of IAG, in addition to its role as a masculinization-inducing factor, and also constitute the basis for a discussion of the evolutionary relationship between the above two species.
[Mh] Termos MeSH primário: Astacoidea/genética
Hormônios Gonadais/genética
Insulina/genética
Partenogênese/genética
[Mh] Termos MeSH secundário: Sequência de Aminoácidos
Animais
Sequência de Bases
Feminino
Biblioteca Gênica
Genoma
Hormônios Gonadais/química
Hormônios Gonadais/metabolismo
Insulina/química
Insulina/metabolismo
Masculino
Filogenia
RNA Mensageiro/genética
RNA Mensageiro/metabolismo
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Gonadal Hormones); 0 (Insulin); 0 (RNA, Messenger)
[Em] Mês de entrada:1801
[Cu] Atualização por classe:180108
[Lr] Data última revisão:
180108
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:171221
[St] Status:MEDLINE
[do] DOI:10.1371/journal.pone.0189982


  2 / 500 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28689667
[Au] Autor:Ethier JL; Desautels DN; Amir E; MacKay H
[Ad] Endereço:Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre and Department of Medicine, University of Toronto, Toronto, Canada. Electronic address: josee-lyne.ethier@uhn.ca.
[Ti] Título:Is hormonal therapy effective in advanced endometrial cancer? A systematic review and meta-analysis.
[So] Source:Gynecol Oncol;147(1):158-166, 2017 Oct.
[Is] ISSN:1095-6859
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: Hormonal therapy (HT) is used commonly in the treatment of advanced endometrial cancer (EC). However, a 2010 Cochrane Review did not show a survival benefit for HT. Here, we quantify its effects and explore the influence of clinico-pathologic factors and hormone receptor (HR) status on overall response rates (ORR). METHODS: A systematic search of electronic databases identified publications of HT in advanced EC. Data from individual studies reporting ORR, median progression-free (PFS) or overall survival (OS) were weighted by individual study sample size and pooled in a meta-analysis. Outcomes of estrogen (ER) and progesterone receptor (PgR) subgroups were collected. Studies of first- and second-line HT were analyzed independently. Mixed studies were included if subgroup data based on previous HT exposure were provided. Meta-regression was performed to evaluate the influence of clinico-pathologic factors on outcomes. RESULTS: Thirty-nine studies were included, with seven providing subgroup data based on HR status. First-line HT was associated with a mean ORR of 21.6% and clinical benefit rate (CBR) of 36.7%. Median PFS and OS were 2.8 and 10.2months respectively. ORR was 20.4% in clinical trials and 25.3% in observational studies. Magnitude of ORR was lower in older age, adenosquamous histology and high grade. ORR was higher in ER+ (26.5%) and PgR+ (35.5%) disease, and lower in ER- (9.2%) or PgR- (12.1%) tumors. Second-line ORR was 18.5%. CBR was 35.8%, but was significantly associated with timing of stable disease assessments in first- and second-line. Meta-regression performed in mixed and second-line studies showed an association between previous HT and greater ORR (ß 0.561; p=0.024), suggesting potential confounding by indication (re-treatment of good responders to first-line HT). CONCLUSION: HT is associated with modest ORR in advanced EC, and is greatest in HR+ tumors. Response rates in second-line are likely dependent on response to previous HT.
[Mh] Termos MeSH primário: Antineoplásicos Hormonais/uso terapêutico
Neoplasias do Endométrio/tratamento farmacológico
Hormônios Gonadais/uso terapêutico
Antagonistas de Hormônios/uso terapêutico
[Mh] Termos MeSH secundário: Quimioterapia Combinada
Neoplasias do Endométrio/química
Neoplasias do Endométrio/patologia
Feminino
Seres Humanos
Moduladores Seletivos de Receptor Estrogênico/uso terapêutico
Análise de Sobrevida
[Pt] Tipo de publicação:JOURNAL ARTICLE; META-ANALYSIS; REVIEW
[Nm] Nome de substância:
0 (Antineoplastic Agents, Hormonal); 0 (Gonadal Hormones); 0 (Hormone Antagonists); 0 (Selective Estrogen Receptor Modulators)
[Em] Mês de entrada:1709
[Cu] Atualização por classe:170926
[Lr] Data última revisão:
170926
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170711
[St] Status:MEDLINE


  3 / 500 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28632729
[Au] Autor:Moskowitz CS; Chou JF; Sklar CA; Barnea D; Ronckers CM; Friedman DN; Neglia JP; Turcotte L; Howell RM; Henderson TO; Armstrong GT; Leisenring WM; Robison LL; van Leeuwen FE; Pike MC; Oeffinger KC
[Ad] Endereço:Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY 10017, USA.
[Ti] Título:Radiation-associated breast cancer and gonadal hormone exposure: a report from the Childhood Cancer Survivor Study.
[So] Source:Br J Cancer;117(2):290-299, 2017 Jul 11.
[Is] ISSN:1532-1827
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: The relationship between hormone exposure and breast cancer risk in women treated with chest radiotherapy for childhood cancer is uncertain. METHODS: Participants included 1108 females from the Childhood Cancer Survivor Study who were diagnosed with childhood cancer 1970-1986, treated with chest radiotherapy, and survived to ages ⩾20 years. Hazard ratios (HRs) and 95% confidence intervals (CIs) from Cox models adjusted for chest radiation field, delivered dose, anthracycline exposure, and age at childhood cancer estimated risk. RESULTS: Among 195 women diagnosed with breast cancer, 102 tumours were oestrogen-receptor positive (ER+). Breast cancer risk increased with ⩾10 years of ovarian function after chest radiotherapy vs <10 years (HR=2.89, CI 1.56-5.53) and for radiotherapy given within 1 year of menarche vs >1 year from menarche (HR=1.80, CI 1.19-2.72). Risk decreased with decreasing age at menopause (P =0.014). Risk factors did not differ for ER+ breast cancer. Survivors with an age at menopause <20 years treated with hormone therapy had a lower breast cancer risk than premenopausal survivors (HR=0.47, CI 0.23-0.94). CONCLUSIONS: Endogenous hormones are key contributors to breast cancer observed among childhood cancer survivors. Hormone therapy given for premature ovarian insufficiency does not fully replace the function that endogenous hormones have in breast cancer development.
[Mh] Termos MeSH primário: Neoplasias da Mama/tratamento farmacológico
Terapia de Reposição Hormonal
Neoplasias Induzidas por Radiação/tratamento farmacológico
Radioterapia/efeitos adversos
[Mh] Termos MeSH secundário: Adulto
Neoplasias da Mama/patologia
Neoplasias da Mama/radioterapia
Criança
Receptor alfa de Estrogênio/genética
Feminino
Hormônios Gonadais/genética
Hormônios Gonadais/uso terapêutico
Seres Humanos
Meia-Idade
Neoplasias Induzidas por Radiação/genética
Neoplasias Induzidas por Radiação/patologia
Fatores de Risco
Sobreviventes
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Estrogen Receptor alpha); 0 (Gonadal Hormones); 0 (estrogen receptor alpha, human)
[Em] Mês de entrada:1708
[Cu] Atualização por classe:171026
[Lr] Data última revisão:
171026
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170621
[St] Status:MEDLINE
[do] DOI:10.1038/bjc.2017.169


  4 / 500 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28628359
[Au] Autor:Link JC; Reue K
[Ad] Endereço:Department of Human Genetics, David Geffen School of Medicine, University of California, Los Angeles, California 90095; email: reuek@ucla.edu.
[Ti] Título:Genetic Basis for Sex Differences in Obesity and Lipid Metabolism.
[So] Source:Annu Rev Nutr;37:225-245, 2017 Aug 21.
[Is] ISSN:1545-4312
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Men and women exhibit significant differences in obesity, cardiovascular disease, and diabetes. To provide better diagnosis and treatment for both sexes, it is important to identify factors that underlie the observed sex differences. Traditionally, sex differences have been attributed to the differential effects of male and female gonadal secretions (commonly referred to as sex hormones), which substantially influence many aspects of metabolism and related diseases. Less appreciated as a contributor to sex differences are the fundamental genetic differences between males and females, which are ultimately determined by the presence of an XX or XY sex chromosome complement. Here, we review the mechanisms by which gonadal hormones and sex chromosome complement each contribute to lipid metabolism and associated diseases, and the current approaches that are used to study them. We focus particularly on genetic approaches including genome-wide association studies in humans and mice, -omics and systems genetics approaches, and unique experimental mouse models that allow distinction between gonadal and sex chromosome effects.
[Mh] Termos MeSH primário: Hormônios Gonadais
Metabolismo dos Lipídeos/genética
Obesidade/genética
Cromossomos Sexuais
[Mh] Termos MeSH secundário: Animais
Feminino
Seres Humanos
Masculino
Camundongos
Caracteres Sexuais
Fatores Sexuais
[Pt] Tipo de publicação:JOURNAL ARTICLE; REVIEW
[Nm] Nome de substância:
0 (Gonadal Hormones)
[Em] Mês de entrada:1710
[Cu] Atualização por classe:171002
[Lr] Data última revisão:
171002
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170620
[St] Status:MEDLINE
[do] DOI:10.1146/annurev-nutr-071816-064827


  5 / 500 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28522409
[Au] Autor:Zhang H; Taya K; Nagaoka K; Yoshida M; Watanabe G
[Ad] Endereço:Laboratory of Animal Physiology, College of Biological Sciences and Technology, Beijing Forestry University, Beijing 100083, PR China; United Graduate School of Veterinarian Science, Gifu University, Gifu 501-1193, Japan; Laboratory of Veterinary Physiology, Cooperative Department of Veterinary Medi
[Ti] Título:Neonatal exposure to 17α-ethynyl estradiol (EE) disrupts follicle development and reproductive hormone profiles in female rats.
[So] Source:Toxicol Lett;276:92-99, 2017 Jul 05.
[Is] ISSN:1879-3169
[Cp] País de publicação:Netherlands
[La] Idioma:eng
[Ab] Resumo:Toxic effects induced by exposure to endocrine-disrupting chemicals during fetal and neonatal periods can be irreversible and exert effects throughout an animal's entire life. Our previous study showed that neonatal exposure to 17α-ethynyl estradiol (EE) induced irregular estrous cycle in adults. To uncover the reason for the delayed effect after neonatal exposure to EE, reproductive parameters including ovarian weight, ovarian steroidogenesis, and hormonal profiles were investigated in developing female rats. Ovarian weight decreased at postnatal days (PND) 14 and 21 after neonatal exposure to EE. Ovarian histology at PND21 showed that the ratio of follicles with a diameter >300µm decreased and the ratio of follicles with a diameter of 100-150µm increased in EE-treated ovaries, indicating that neonatal exposure to EE retarded follicular development. Moreover, the expression of P450arom increased at PND14 and the expressions of inhibin/activin subunits ßA and ßB decreased at PND21 in EE-treated ovaries. Consistent with the expression of P450arom, circulating levels of 17ß-estradiol increased at PND14 in EE-treated animals. Furthermore, the circulating levels of luteinizing hormone (LH) also increased at PND14 in the treated animals. Although the expression of Kiss1 did not change in the anteroventral periventricular nucleus (AVPV) of the hypothalamus between controls and EE-treated rats, the expression of Kiss1 was reduced in the arcuate nucleus (ARC) of the hypothalamus at PND14. Based upon those results, we suggest that neonatal exposure to EE disrupted the system regulating the interactions between the reproductive hormones and follicle development in pre-pubertal rats, which may result in reproduction dysfunction in adulthood.
[Mh] Termos MeSH primário: Disruptores Endócrinos/toxicidade
Etinilestradiol/toxicidade
Hormônios Gonadais/metabolismo
Folículo Ovariano/efeitos dos fármacos
Ovário/efeitos dos fármacos
Reprodução/efeitos dos fármacos
[Mh] Termos MeSH secundário: Animais
Animais Recém-Nascidos
Núcleo Arqueado do Hipotálamo/efeitos dos fármacos
Núcleo Arqueado do Hipotálamo/metabolismo
Aromatase/genética
Aromatase/metabolismo
Proliferação Celular/efeitos dos fármacos
Estradiol/sangue
Feminino
Hormônios Gonadais/sangue
Subunidades beta de Inibinas/metabolismo
Kisspeptinas/genética
Kisspeptinas/metabolismo
Hormônio Luteinizante/sangue
Tamanho do Órgão/efeitos dos fármacos
Folículo Ovariano/metabolismo
Folículo Ovariano/patologia
Ovário/metabolismo
Ovário/patologia
Ratos Wistar
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Endocrine Disruptors); 0 (Gonadal Hormones); 0 (Kiss1 protein, rat); 0 (Kisspeptins); 0 (inhibin beta A subunit); 423D2T571U (Ethinyl Estradiol); 4TI98Z838E (Estradiol); 9002-67-9 (Luteinizing Hormone); 93443-12-0 (Inhibin-beta Subunits); EC 1.14.14.1 (Aromatase)
[Em] Mês de entrada:1708
[Cu] Atualização por classe:170808
[Lr] Data última revisão:
170808
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170520
[St] Status:MEDLINE


  6 / 500 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28389909
[Au] Autor:Wiechno PJ; Kowalska M; Kucharz J; Sadowska M; Michalski W; Poniatowska G; Jonska-Gmyrek J; Rzymkowska J; Nietupski K; Demkow T
[Ad] Endereço:Department of Uro-Oncology, Maria Sklodowska-Curie Memorial Cancer Center and Institute of Oncology, Roentgena 5 st., 02-781, Warsaw, Poland.
[Ti] Título:Dynamics of hormonal disorders following unilateral orchiectomy for a testicular tumor.
[So] Source:Med Oncol;34(5):84, 2017 May.
[Is] ISSN:1559-131X
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Testicular tumors and their treatment interfere with homeostasis, hormonal status included. The aim of the study was to evaluate hormonal disorders of the pituitary-gonadal axis in men treated for testicular tumors. One hundred twenty-eight men treated for a unilateral testicular tumor at our institution were included. The hormonal status was prospectively evaluated in 62 patients before orchiectomy, 120 patients 1 month after orchiectomy and 110 patients at least 1 year after the treatment. The concentrations of human chorionic gonadotropin (hCG), testosterone (T), estradiol, luteinizing hormone (LH), follicle-stimulating hormone (FSH) and prolactin were measured. The clinically significant testosterone deficiency was defined either as testosterone <2.31 ng/mL or testosterone within the range of 2.31-3.46 ng/mL but simultaneous with T/LH ratio ≤1. Changes in hormone levels were significant: LH and FSH rose in the course of observation, and the concentration of hCG, testosterone, estradiol decreased. PRL concentration was the lowest at 1 month after orchiectomy. In multivariate analysis, the risk of the clinically significant testosterone deficiency was 0.2107 (95% CI 0.1206-0.3419) prior to orchiectomy, 0.3894 (95% CI 0.2983-0.4889) 1 month after surgery and 0.4972 (95% CI 0.3951-0.5995) 1 year after the treatment. The estradiol concentration was elevated in 40% of patients with recently diagnosed testicular cancer and that was correlated with a higher risk of testosterone deficiency after the treatment completion. Hormonal disorders of the pituitary-gonadal axis in men treated for testicular tumors are frequent. The malignant tissue triggers paraneoplastic disorders that additionally disturb the hormonal equilibrium.
[Mh] Termos MeSH primário: Hormônios Gonadais/metabolismo
Orquiectomia/efeitos adversos
Hormônios Hipofisários/metabolismo
Neoplasias Testiculares/cirurgia
[Mh] Termos MeSH secundário: Adolescente
Adulto
Gonadotropina Coriônica/metabolismo
Estradiol/metabolismo
Hormônio Foliculoestimulante/metabolismo
Seres Humanos
Hormônio Luteinizante/metabolismo
Masculino
Meia-Idade
Orquiectomia/métodos
Hipófise/metabolismo
Prolactina/metabolismo
Testículo/metabolismo
Testosterona/deficiência
Testosterona/metabolismo
Adulto Jovem
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Chorionic Gonadotropin); 0 (Gonadal Hormones); 0 (Pituitary Hormones); 3XMK78S47O (Testosterone); 4TI98Z838E (Estradiol); 9002-62-4 (Prolactin); 9002-67-9 (Luteinizing Hormone); 9002-68-0 (Follicle Stimulating Hormone)
[Em] Mês de entrada:1704
[Cu] Atualização por classe:170425
[Lr] Data última revisão:
170425
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170409
[St] Status:MEDLINE
[do] DOI:10.1007/s12032-017-0943-0


  7 / 500 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28292621
[Au] Autor:Belva F; Roelants M; Vloeberghs V; Schiettecatte J; Evenepoel J; Bonduelle M; de Vos M
[Ad] Endereço:Center for Medical Genetics, Universitair Ziekenhuis Brussel, Brussels, Belgium. Electronic address: florence_belva@hotmail.com.
[Ti] Título:Serum reproductive hormone levels and ultrasound findings in female offspring after intracytoplasmic sperm injection: first results.
[So] Source:Fertil Steril;107(4):934-939, 2017 Apr.
[Is] ISSN:1556-5653
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:OBJECTIVE: To compare reproductive hormone levels and antral follicle count in intracytoplasmic sperm injection (ICSI)-conceived offspring and peers born after spontaneous conception. DESIGN: Single-center study of the reproductive health at the age of 18-22 years in the worldwide oldest cohort of female ICSI offspring. SETTING: University hospital. PATIENT(S): A longitudinally followed cohort of singleton women (n = 71) conceived by means of ICSI because of male infertility and a cross-sectionally recruited group of spontaneously conceived women of the same age (n = 81). INTERVENTIONS(S): None. MAIN OUTCOME MEASURE(S): Differences in serum reproductive hormone levels and ultrasound findings. RESULT(S): Median levels of antimüllerian hormone (AMH), FSH, LH, and DHEAS were similar between ICSI women and their spontaneously conceived counterparts. Median E levels in ICSI women taking hormonal contraceptives were higher compared with control women. A minority of ICSI women had AMH levels below the 5th or above the 95th percentile, and ICSI women were not more likely to have AMH levels below the 5th percentile or above the 95th percentile compared with control women. Mean follicle count per ovary was similar between the ICSI and control groups. Furthermore, a similar proportion of women had >19 follicles per ovary (ICSI: 20.9%; control: 20.0%). A strong positive correlation between AMH level and mean follicle count per ovary was found. CONCLUSION(S): In this cohort of 71 young adult women conceived by means of ICSI because of male infertility in their parents, antral follicle count and circulating reproductive hormone levels, including AMH, FSH, LH, and DHEAS, were found to be similar to results from peers born after spontaneous conception.
[Mh] Termos MeSH primário: Crianças Adultas
Fertilidade
Hormônios Gonadais/sangue
Infertilidade Masculina/terapia
Folículo Ovariano/diagnóstico por imagem
Injeções de Esperma Intracitoplásmicas
Ultrassonografia
[Mh] Termos MeSH secundário: Adolescente
Hormônio Antimülleriano/sangue
Biomarcadores/sangue
Estudos de Casos e Controles
Sulfato de Desidroepiandrosterona/sangue
Feminino
Hormônio Foliculoestimulante Humano/sangue
Hospitais Universitários
Seres Humanos
Infertilidade Masculina/diagnóstico
Infertilidade Masculina/fisiopatologia
Nascimento Vivo
Hormônio Luteinizante/sangue
Masculino
Valor Preditivo dos Testes
Saúde Reprodutiva
Resultado do Tratamento
Adulto Jovem
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Biomarkers); 0 (Follicle Stimulating Hormone, Human); 0 (Gonadal Hormones); 57B09Q7FJR (Dehydroepiandrosterone Sulfate); 80497-65-0 (Anti-Mullerian Hormone); 9002-67-9 (Luteinizing Hormone)
[Em] Mês de entrada:1706
[Cu] Atualização por classe:170605
[Lr] Data última revisão:
170605
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170316
[St] Status:MEDLINE


  8 / 500 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28264433
[Au] Autor:McGrice M; Porter J
[Ad] Endereço:Dietetics Department, Eastern Health, 5 Arnold Street, Box Hill VIC 3128, Australia. melanie@nutritionplus.com.au.
[Ti] Título:The Effect of Low Carbohydrate Diets on Fertility Hormones and Outcomes in Overweight and Obese Women: A Systematic Review.
[So] Source:Nutrients;9(3), 2017 Feb 27.
[Is] ISSN:2072-6643
[Cp] País de publicação:Switzerland
[La] Idioma:eng
[Ab] Resumo:(1) Background: Medical interventions including assisted reproductive technologies have improved fertility outcomes for many sub-fertile couples. Increasing research interest has investigated the effect of low carbohydrate diets, with or without energy restriction. We aimed to systematically review the published literature to determine the extent to which low carbohydrate diets can affect fertility outcomes; (2) Methods: The review protocol was registered prospectively with Prospective Register for Systematic Reviews (registration number CRD42016042669) and followed Preferred Reporting Items For Systematic Reviews and Meta-Analyses guidelines. Infertile women were the population of interest, the intervention was low carbohydrate diets (less than 45% total energy from carbohydrates), compared to usual diet (with or without co-treatments). Four databases were searched from date of commencement until April 2016; a supplementary Google scholar search was also undertaken. Title and abstract, then full text review, were undertaken independently and in duplicate. Reference lists of included studies and relevant systematic reviews were checked to ensure that all relevant studies were identified for inclusion. Quality assessment was undertaken independently by both authors using the Quality Criteria Checklist for Primary Research. Outcome measures were improved fertility outcomes defined by an improvement in reproductive hormones, ovulation rates and/or pregnancy rates; (3) Results: Seven studies fulfilled the inclusion criteria and were included in the evidence synthesis. Interventions were diverse and included a combination of low carbohydrate diets with energy deficit or other co-treatments. Study quality was rated as positive for six studies, suggesting a low risk of bias, with one study rated as neutral. Of the six studies which reported changes in reproductive hormones, five reported significant improvements post intervention; (4) Conclusion: The findings of these studies suggest that low carbohydrate diets warrant further research to determine their effect. These randomised controlled trials should consider the effect of carbohydrates (with or without energy deficit) on hormonal and fertility outcomes.
[Mh] Termos MeSH primário: Dieta com Restrição de Carboidratos
Infertilidade Feminina/dietoterapia
Obesidade/sangue
Sobrepeso/sangue
Resultado da Gravidez
[Mh] Termos MeSH secundário: Bases de Dados Factuais
Medicina Baseada em Evidências
Feminino
Fertilidade
Hormônios Gonadais/sangue
Seres Humanos
Metanálise como Assunto
Gravidez
Taxa de Gravidez
Estudos Prospectivos
Ensaios Clínicos Controlados Aleatórios como Assunto
[Pt] Tipo de publicação:JOURNAL ARTICLE; REVIEW
[Nm] Nome de substância:
0 (Gonadal Hormones)
[Em] Mês de entrada:1708
[Cu] Atualização por classe:170817
[Lr] Data última revisão:
170817
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170308
[St] Status:MEDLINE


  9 / 500 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28235100
[Au] Autor:Zhang D; Sun M; Liu X
[Ad] Endereço:Key Laboratory of East China Sea & Oceanic Fishery Resources Exploitation and Utilization, Ministry of Agriculture, Shanghai, P. R. China.
[Ti] Título:Phase-specific expression of an insulin-like androgenic gland factor in a marine shrimp Lysmata wurdemanni: Implication for maintaining protandric simultaneous hermaphroditism.
[So] Source:PLoS One;12(2):e0172782, 2017.
[Is] ISSN:1932-6203
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: Shrimp in the genus Lysmata have a unique and rare sexual system referred to as protandric simultaneous hermaphroditism, whereby individuals mature first as male (male phase), and then the female function may also develop as the shrimp grow, so that the gonad is able to produce both eggs and sperms simultaneously, a condition called simultaneous hermaphroditism (euhermaphrodite phase). To date, the mechanisms of sex control in this sexual system still remain poorly understood. Many studies indicate that an insulin-like androgenic gland factor (IAG) is involved in controlling sex differentiation in gonochoric crustaceans, but its role in the protandric simultaneous hermaphrodite is still not clear. RESULTS: To determine whether an IAG is involved in sex control in the hermaphrodite, here we, for the first time, cloned the IAG gene cDNA sequence from Lysmata wurdemanni (termed Lw-IAG: L. wurdemanni insulin-like AG factor), a protandric simultaneous hermaphroditic shrimp. The IAG contains an open reading frame of 528 bp, corresponding to 176 amino acids, which consists of a signal peptide, B chain, C peptide, and A chain. The organization is similar to the IAGs found in other decapods. The IAG gene was expressed in both male and euhermaphrodite phases, but the expression level was significantly higher in the male phase than in the euhermaphrodite phase. Immunofluorescence analysis and Western Blotting revealed that the IAG protein was expressed in the androgenic gland, and its expression level was higher in the male phase than in the euhermaphrodite phase. CONCLUSIONS: Data presented here suggest that the IAG gene may be a factor controlling sex in the protandric simultaneous hermaphrodite, and that the euhermaphrodite phase is maintained by reduced gene expression, i.e., the presence of the androgenic gland (or the androgenic hormone it produces) completely inhibits ovarian development in the male phase, and incomplete degeneration of the androgenic gland in the euhermaphrodite phase results in simultaneous hermaphroditism. The findings presented in the current study can help to reveal how protandric simultaneous hermaphroditism evolved in crustaceans.
[Mh] Termos MeSH primário: Transtornos do Desenvolvimento Sexual/genética
Hormônios Gonadais/genética
Insulina/metabolismo
Processos de Determinação Sexual
[Mh] Termos MeSH secundário: Androgênios/genética
Androgênios/metabolismo
Animais
Proteínas de Artrópodes/genética
DNA Complementar/genética
Gônadas/crescimento & desenvolvimento
Gônadas/metabolismo
Insulina/genética
Penaeidae/genética
Penaeidae/crescimento & desenvolvimento
Processos de Determinação Sexual/genética
Diferenciação Sexual/genética
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Androgens); 0 (Arthropod Proteins); 0 (DNA, Complementary); 0 (Gonadal Hormones); 0 (Insulin)
[Em] Mês de entrada:1708
[Cu] Atualização por classe:170815
[Lr] Data última revisão:
170815
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170225
[St] Status:MEDLINE
[do] DOI:10.1371/journal.pone.0172782


  10 / 500 MEDLINE  
              first record previous record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28009091
[Au] Autor:Baumgartner C; Hubacher T; Krayer M; Gschossmann J
[Ad] Endereço:Department of Visceral Surgery and Medicine, University Hospital of Berne, Bern, Switzerland.
[Ti] Título:In vitro spontaneous contractile activity of colonic smooth muscle in naive Lewis rats: Acute effect of gonadal hormones.
[So] Source:J Dig Dis;18(1):13-22, 2017 Jan.
[Is] ISSN:1751-2980
[Cp] País de publicação:Australia
[La] Idioma:eng
[Ab] Resumo:OBJECTIVE: Functional gastrointestinal disorders affect females more often. Changes in colonic motility may be etiological co-factors for the clinical symptoms. The aim of the present study was to analyze the influence of gonadal hormones on colonic contractile activity. METHODS: In vitro measurements of colonic contractile activity in longitudinal smooth muscle strips of female and male Lewis rats were performed in an organ chamber experiment. After the administration of a gonadal hormone estradiol [EST], progesterone [PROG] and testosterone [TEST]) or ethanol solution as control, stimulation with acetylcholine (ACh) or inhibition with norepinephrine (NE) was performed. RESULTS: Compared to the smooth muscle strips of male rats, significantly higher spontaneous colonic contractile activity (SCCA) was observed in female animals. Increasing doses of ACh showed the progressive stimulation of SCCA whereas rising doses of NE resulted in a stepwise inhibition of SCCA, respectively. EST superfusion displayed an inhibitory effect on SCCA in both sexes and inhibited the ACh effect in female rats. Similarly, acute superfusion with high-dose PROG inhibited SCCA in females. Acute TEST superfusion inhibited SCCA in males and led to significant higher colonic contractile activity in males following subsequent stimulation with ACh. In female rats, the inhibitory effect of NE was reduced by prior exposure to TEST. CONCLUSION: In our in vitro study the acute exposure of colonic smooth muscle tissue to gonadal hormones led to sex-dependent changes in SCCA and translated in a modified response of smooth muscle strips to both pro-contractile and anti-contractile neurotransmitters.
[Mh] Termos MeSH primário: Colo/efeitos dos fármacos
Motilidade Gastrointestinal/efeitos dos fármacos
Hormônios Gonadais/farmacologia
Contração Muscular/efeitos dos fármacos
Músculo Liso/efeitos dos fármacos
[Mh] Termos MeSH secundário: Acetilcolina/administração & dosagem
Acetilcolina/farmacologia
Animais
Colo/fisiologia
Relação Dose-Resposta a Droga
Interações Medicamentosas
Estradiol/farmacologia
Feminino
Motilidade Gastrointestinal/fisiologia
Masculino
Contração Muscular/fisiologia
Músculo Liso/fisiologia
Neurotransmissores/farmacologia
Norepinefrina/farmacologia
Progesterona/farmacologia
Ratos Endogâmicos Lew
Caracteres Sexuais
Testosterona/farmacologia
Técnicas de Cultura de Tecidos
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Gonadal Hormones); 0 (Neurotransmitter Agents); 3XMK78S47O (Testosterone); 4G7DS2Q64Y (Progesterone); 4TI98Z838E (Estradiol); N9YNS0M02X (Acetylcholine); X4W3ENH1CV (Norepinephrine)
[Em] Mês de entrada:1709
[Cu] Atualização por classe:170911
[Lr] Data última revisão:
170911
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:161224
[St] Status:MEDLINE
[do] DOI:10.1111/1751-2980.12438



página 1 de 50 ir para página                         
   


Refinar a pesquisa
  Base de dados : MEDLINE Formulário avançado   

    Pesquisar no campo  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/OPAS/OMS - Centro Latino-Americano e do Caribe de Informação em Ciências da Saúde